5HT-2c AGONIST LORCASERIN DECREASES CANNABIS SELF-ADMINISTRATION IN DAILY CANNABIS SMOKERS

There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2c agonist, lorcaserin, attenuates cue-induced reinstatement of THC-seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Addict Biol
Prif Awduron: Arout, Caroline A., Cooper, Ziva D., Reed, Stephanie Collins, Foltin, Richard W., Comer, Sandra D., Levin, Frances R., Haney, Margaret
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225547/
https://ncbi.nlm.nih.gov/pubmed/33389797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/adb.12993
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg